UK needs two-tier National Health Service.
D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D009313:National Health Programs / Q000191:economics* / Q000331:legislation & jurisprudence / Q000458:organization & administration; D011306:Prescription Fees / Q000331:legislation & jurisprudence*; D006113:United Kingdom
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab